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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the impact of indoor residual spraying (IRS) on malaria disease burden.
B A C K G R O U N D
Description of the condition
Malaria is a parasitic disease caused by a number of Plasmodium
species, and is transmitted by the bite of female mosquitoes from
several Anopheles species (WHO 2018a). Plasmodium falciparum
and Plasmodium vivax are the most prevalent parasite species; P
falciparum is responsible for the most deaths. Despite decades of
control activities, malaria continues to cause more deaths than any
other parasitic disease worldwide, and it impedes socioeconomic
development. Annual incidence has declined since 2010; how-
ever, in more recent years progress in malaria control has stalled,
with no significant reduction in malaria cases observed between
2015 to 2017. Over 219 million cases and 435,000 malaria-re-
lated deaths are estimated to have occurred globally in 2017, and
approximately half of the global population is believed to be at
risk of malaria (WHO 2018a). This burden is disproportionately
distributed; almost 80% of malaria cases occur in 15 sub-Saharan
African countries and India, and 93% of deaths from malaria oc-
cur in Africa. Individuals most at risk of dying from malaria are
those with low levels of immunity, reduced access to healthcare
services, and those who are highly exposed to infectious bites.
Globally, major barriers to achieving malaria control and elimina-
tion include the emergence of Plasmodium resistance to antimalar-
ialmedications;Anopheles resistance to insecticides; conflict, which
limits the delivery of healthcare services in endemic regions; inad-
equate funding; and lack of an effective vaccine (Alonso 2013).
Description of the intervention
Indoor residual spraying (IRS) involves the application of insecti-
cide products to the interior surfaces (walls and ceilings) of house-
holds, public buildings, or animal dwellings in areas where indi-
viduals are considered at risk of malaria (or other vector-borne
diseases, including Chagas disease and leishmaniasis). It is most
effective against endophilic (indoor-resting), endophagic (indoor-
biting) mosquitoes from the Anopheles species that rest on these
surfaces. The vector control group of theWorld Health Organiza-
tion (WHO)Prequalification Team recommends numerous insec-
ticidal chemicals for use in IRS, such as organophosphates, carba-
mates, pyrethroids, and dichlorodiphenyltrichloroethane (DDT;
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the only organochlorine that is solely recommended when no af-
fordable alternative is available). Clothianidin (a neonicotinoid
insecticide) has recently been added to this list, and an interim
recommendation has been made for chlorfenapyr, an insecticide
belonging to a class known as halogenated pyrroles (WHO 2015;
WHO 2018b). Depending on the conditions in the given setting
(for example, seasonality of transmission, and duration of effective
action of the insecticide being utilized), IRS needs to be repeated
every three to nine months in targeted areas, over large geograph-
ical areas, or applied in areas identified as malaria hotspots. It may
be undertaken as a preventative measure or in response to cases
being detected.
Indoor residual spraying has been widely used in malaria control
programmes worldwide since the 1940s. The success of the Global
Malaria Eradication Campaign (GMEP) between 1955 and 1969
has been largely attributed to large-scale DDT-IRS campaigns
(Najera 2011).
Following the introduction of IRS with DDT under national
malaria control programmes implemented during the 1940s,
1950s, and 1960s, malaria was eliminated in many regions, and
sharp declines in infection and vector densities were reported in
other areas, such as Southern Africa and India (Mabaso 2004).
While IRS remains a core malaria control activity in several coun-
tries worldwide, including regions of South America and India,
population coverage has declined on both regional and global
scales since 2010, as insecticide-treated net (ITN) coverage has in-
creased (WHO2018a). Additional factors which have contributed
to the reduced use of IRS include lack of government commitment
to funding IRS programmes, and concerns regarding commu-
nity acceptance and the selection of insecticide resistance (WHO
2006a).
How the intervention might work
Most female Anopheles mosquitoes are endophagic, endophilic,
and night-biting. Indoor residual spraying exploits these be-
haviours, and protects individuals from malaria transmission,
through targeting and killing mosquitoes that rest on a wall after
blood feeding (WHO 2015). This aims to reduce abundance and
shorten the average mosquito’s lifespan to less than the time neces-
sary for Plasmodium to undergo its lifecycle in the vector. In con-
trast to topical repellents and mosquito nets, which provide per-
sonal protection and prevent biting from occurring, IRS operates
largely at a community level and targets vectors that have already
taken a blood meal. High coverage (usually more than 85% of all
potential indoor resting sites) therefore needs to be achieved for
IRS to be effective.
Due to financial and logistical implications, the WHO recom-
mends that IRS be prioritized only in regions that experience a sin-
gle annual peak in malaria transmission and have densely spaced
housing, or where a rapid decline in vector density needs to be
achieved, for example during an outbreak (WHO 2015). Other
interventions, particularly ITNs, are alternatively recommended
for contexts where long-term vector control needs to be sustained
(WHO 2006b).
Why it is important to do this review
Following the discovery of DDT in the 1940s, IRS became popu-
larized and its success in various pilot projects across the world ul-
timately inspired the initiation of the GMEP, with IRS featured as
a core component (Nájera 1999). This happened at a time where
high-quality evidence was not a prerequisite for vector control pol-
icy recommendations, and the subsequent success of the GMEP
programme in many parts of the world meant that the efficacy of
IRS as a malaria control intervention was widely accepted. For this
reason, only a limited number of studies using strong experimental
designs have been conducted.
A Cochrane Review evaluating IRS, Pluess 2010, was restricted
to randomized controlled trials (RCTs) with three units per study
arm, controlled before-and-after studies (CBAs), and interrupted
time series (ITS) analyses. Six studies met the inclusion crite-
ria and the results on the effect of IRS in different transmission
settings were inconclusive. There has been repeated criticism of
the review because observational studies were excluded, despite
the substantial evidence base for IRS that was generated prior to
the widespread adoption of experimental designs for community
malaria interventions (WHO 2017). For this new Cochrane Re-
view, we will include prospective cohort studies, quasi-experimen-
tal randomized studies, and RCTs with two units per study arm,
in addition to RCTs with three units per study arm, CBAs, and
ITS studies.
It remains unclear whether there are significant additional benefits
of adding IRS to ITNs, and this is a question that will be addressed
in a separate Cochrane review (Choi 2017). In order to minimize
the risk of diluting or overestimating the effect of IRS alone on
malaria transmission, we have therefore chosen to exclude studies
where there is thought to be moderate to high coverage of ITNs.
For this reason, we will exclude all studies conducted after 2003
due to the known widespread coverage of ITNs in Africa at this
time, and increases in ITN coverage globally from 2003 onwards
(Bhatt 2015; Noor 2009).
O B J E C T I V E S
Toevaluate the impact of indoor residual spraying (IRS) onmalaria
disease burden.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
Cluster-randomized controlled trials (cRCTs) with:
• baseline data;
• monitoring of at least one transmission season; and
• at least two clusters per arm.
Quasi-experimental designs including stepped wedge where sites
are randomly allocated.
Interrupted time series (ITS) designs with:
• a clearly defined point in time when the intervention
occurred; and
• at least three data points before, and three after, the
intervention.
Randomized cross-over studies and non-randomized cross-over
studies with:
• a clearly defined point in time when the cross-over
occurred; and
• monitoring of at least two transmission seasons before and
after the cross-over.
Controlled before-and-after studies (CBAs) with:
• a contemporaneous control group; and
• monitoring of at least one transmission season before and
after the intervention; and at least two sites per study arm.
Prospective cohort studies with:
• baseline data and exclusion of existing cases to ensure
exposure preceded outcome; and
• monitoring of at least two transmission seasons following
baseline data collection.
Types of participants




Indoor residual spraying (IRS) using the insecticides recom-
mended by the WHO, at the appropriate target dosage (Table 1).
Control
• No other insecticidal malaria vector control interventions;
or
• IRS using an alternative regimen, including IRS sprayed at
an alternative point in time or alternative frequency.
Any other interventions for malaria control, such as mass drug
administration and untreated mosquito nets, must be delivered
in both the intervention and control arms, at the same level of
delivery.
Due to the known widespread coverage of ITNs in Africa, and
increases in ITN coverage globally from 2003 onwards, we will
exclude all studies conducted after 2003 from the review (Noor
2009).
Types of outcome measures
To be eligible for inclusion, studies must report at least one of the
following primary outcomes.
Primary outcomes
• Malaria case incidence: measured as number of cases per
unit of time or the number of new uncomplicated malaria cases.
We will use site-specific definitions as long as they have
demonstrated: a) a fever or history of fever, and b) confirmed
parasitaemia (by blood smear microscopy, rapid diagnostic test
or PCR).
• Incidence of new malaria infection: measured as count per
person unit time or the number of new infections.
• Parasite prevalence: the proportion of surveyed individuals
with confirmed parasitaemia at a community household survey.
Secondary outcomes
Entomological
• Entomological inoculation rate (EIR): the estimated
number of bites by infectious mosquitoes per person per unit
time. This is measured using the human biting rate (the number
of mosquitoes biting an individual over a stated period,
measured directly using human baits or indirectly using light
traps, knock-down catches, baited huts, or other methods of
biting rate determination) multiplied by the sporozoite rate.
• Adult mosquito density: measured by a technique
previously shown to be appropriate for the vector (e.g. human
baits, light traps, knock-down catches, baited huts, or other
methods).
• Sporozoite rate: measured as the number of caught adult
mosquitoes positive for malaria sporozoites. Sporozoites can be
detected through molecular or immunological methods.
Epidemiological
• Anaemia prevalence: defined according to WHO cut-offs
based on haemoglobin measurements taken in community
household surveys (Table 2; WHO 2011).
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Adverse effects
• Any indicators of adverse effects of the intervention,
including the following, will be reported in the review:
◦ Reports of poisoning in humans due to increased
exposure to insecticides
◦ Environmental impacts, such as changes to the
biodiversity and ecosystem due to the addition of insecticides.
◦ An increase in the level of phenotypic/molecular
insecticide resistance respective of the class of insecticide used for
IRS confirmed by WHO cylinder assays/Centers for Disease
Control and Prevention (CDC) bottle bioassays/molecular
techniques.
◦ Changes in mosquito behaviour that reduce the
efficacy of vector control interventions, for example an increase
in exophily, exophagy, zoophily, or changes in biting time.
Search methods for identification of studies
Wewill attempt to identify all relevant trials, regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We will search the following databases, using the search terms and
strategy described in Appendix 1: Cochrane Infectious Diseases
Group ( CIDG) Specialized Register; Central Register of Con-
trolled Trials ( CENTRAL), published in the Cochrane Library;
MEDLINE ( Pubmed); Embase ( OVID); Armed Forces Pesticide
Management Board ( AFPMB); CAB Abstracts (Web of Science);
and LILACS .Wewill also search theWHO International Clinical
Trials Registry Platform ( who.int/ictrp/search/en//), ClinicalTri-
als.gov, and the ISRCTN registry ( isrctn.com/) to identify ongo-
ing trials, using “malaria”, “anopheles”, “indoor residual spraying”,
“IRS”, and “house spraying” as search terms.
Searching other resources
We will contact researchers working in the field for unpublished
data. We will also check the citations of all trials identified by the
above methods.
Data collection and analysis
Selection of studies
Two review authors (JFA and SM) will independently assess the
titles and abstracts of studies identified by the searches. The same
two review authors will assess full-text copies of potentially rele-
vant studies for inclusion, using an eligibility form based on the
inclusion criteria. We will compare the results of our assessments
and will resolve any disagreements by discussion and consensus,
with arbitration by a third review author (LC) if necessary.We will
ensure that multiple publications of the same study are included
once. We will list excluded studies, together with their reasons
for exclusion, in a ‘Characteristics of excluded studies’ table. We
will illustrate the study selection process in a PRISMA diagram
(Moher 2009).
We anticipate that primary studies evaluating IRS were carried
out at scale in large programmes with operational before-and-after
comparisons, some of which were probably very important in the
acceptance and adoption of the use of IRS for preventing malaria.
Whilst these studies will be excluded based on our inclusion cri-
teria, we will identify those CBA studies with at least one site per
study arm and summarize these in an additional analysis of pro-
gramme implementation in a review annex.
Data extraction and management
Two review authors (JFA and SM) will independently extract in-
formation from the studies using pre-piloted, electronic data ex-
traction forms. In case of differences in extracted data, the two
review authors will discuss these differences to reach consensus.
If unresolved, we will consult a third review author (LC). In case
of missing data, we will contact the original study author(s) for
clarification.
We will extract data on the following.
• Trial design: type of trial; method of participant selection;
adjustment for clustering (for cRCTs); sample size; method of
blinding of participants and personnel.
• Participants: trial settings and population characteristics;
recruitment rates; withdrawal and loss to follow-up.
• Intervention: description of intervention (active ingredient,
dose, formulation, frequency and timing of application, buffer
zone between clusters); coverage and adherence of the
intervention; any reports of people refusing the intervention and
their reasons behind these decisions.
• Details of cointerventions (for example, mass drug
administration; untreated bednets; active case detection; or
health education); information on coverage and adherence; any
reports of people refusing the intervention and their reasons
behind these decisions.
• Outcomes: definition of outcome; diagnostic method or
surveillance method; passive or active case detection; duration of
follow-up; time points at which outcomes were assessed; number
of events; number of participants or unit time; statistical power;
unit of analysis; incomplete outcomes/missing data.
• Other: primary and secondary vector(s) species; vector(s)
behaviour (population stability, adult habitat, peak biting times,
exophilic/endophilic, exophagic/endophagic, anthropophilic/
zoophilic); method of mosquito collection(s); baseline measures
of phenotypic insecticide resistance and any measures during the
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study period (based on WHO definitions if supplementary
WHO cylinder assays or CDC bottle bioassays or LD50s or
LD95s (lethal dose required to kill 50% or 95% of mosquitoes,
respectively) from larval or adult dose response assays); baseline
measures of genotypic insecticide resistance profile and any
measures during the study period; malaria endemicity; eco-
epidemiological setting; population proximity and density;
Plasmodium species.
For dichotomous outcomes, we will extract the number of patients
experiencing each outcome and the number of patients in each
treatment group. For count/rate data outcomes, we will extract
the number of outcomes in the treatment and control groups, and
the total person time at risk in each group (or the rate ratio), and a
measure of variance (for example, standard error). For continuous
outcomes, we will extract the mean and a measure of variance
(standard deviation).
For cRCTs we will record the number of clusters randomized;
number of clusters analysed; measure of effect (such as risk ratio,
odds ratio, or mean difference) with confidence intervals (CIs) or
standard deviations; number of participants; and the intracluster
correlation coefficient (ICC) value.
For non-randomized studies, we will extract adjusted measures
of intervention effects that attempt to control for confounding.
If no adjusted measures are reported, we will extract unadjusted
measures.
Assessment of risk of bias in included studies
Two review authors (JFA and SM) will independently assess the
risk of bias. For each included cRCT, we will use the Cochrane
‘Risk of bias’ tool, as well as the five additional criteria listed in
Section 16.3.2 of the Cochrane Handbook for Systematic Reviews
of Interventions that relate specifically to cRCTs (Higgins 2011a;
Higgins 2011b). We will assess non-randomized controlled trials
and ITS trials using the ‘Risk of bias’ tool from the Cochrane Ef-
fective Practice and Organisation of Care (EPOC) Group (EPOC
2017). We will classify judgements of risk of bias as either at low,
high, or unclear risk of bias, and we will use summary graphs to
display results.
For observational studies, we will use the Cochrane Risk Of Bias
In Non-randomized Studies - of Interventions (ROBINS-I) tool
(Sterne 2016). We will assess risk of bias through a hierarchy of
domains, starting with critical then serious, moderate, and low.
If any domain reaches critical risk of bias we will not continue
with the assessment, as further evaluation will not influence how
we assess the certainty of the evidence. As the risk of bias in the
effect of an intervention may be different for different outcomes,
we will make a ‘Risk of bias’ assessment for each outcome. The
confounding domains are outlined in Appendix 2.
TheROBINS-I tool recommends only includingnon-randomized
studies that are not classified as having critical risk of bias. For our
main effects analysis, we will follow this approach. As a secondary
analysis, we will perform an analysis of data including studies with
a critical risk of bias to provide an assessment of the degree towhich
different confounding variables may influence effect estimates.We
expect that some studies that have traditionally been used as part
of the evidence base will meet the inclusion criteria, but will be
judged as having critical risk of bias according to ROBINS-I. We
will therefore carry out a subsidiary descriptive analysis for all
studies that are considered to be at critical risk of bias and report
their estimates of effect. We will perform sensitivity analysis for
these studies to describe the effect of confounding.
We will resolve any discrepancies through discussion or by con-
sulting a third review author (LC).
Measures of treatment effect
We will compare intervention and control data using risk ratios or
odds ratios. For count/rate data, we will use rate ratios; for contin-
uous data, we will use the mean difference. We expect incidence
to be reported as either a rate ratio or risk ratio and for prevalence
to be reported as a risk ratio or odds ratio. We will use adjusted
measures of effect to summarize treatment effect from non-ran-
domized studies. We will present all results with their associated
95% CIs.
Unit of analysis issues
For cRCTs, or non-randomized cluster trials, we will extract ad-
justed measures of effect where possible. If the study authors did
not perform any adjustment for clustering, we will adjust the raw
data ourselves using an ICC value. If an ICC is not reported in
the paper, we will obtain this from similar studies, or estimate the
ICC value. We will not present results from cluster-randomized
trials that are not adjusted for clustering. If we estimate the ICC,
we will perform sensitivity analyses to investigate the robustness
of our analyses.
If we identify studies for inclusion that have multiple intervention
arms, we will include data from these studies by either combining
treatment arms, or by splitting the control group so that we only
include these participants in the meta-analysis once.
Dealing with missing data
In case of missing data, we will apply available-case analysis, only
including data on the known results. The denominator will be
the total number of participants who had data recorded for the
specific outcome. For outcomes with no missing data, we plan to
perform analyses on an intention-to-treat basis. We will include
all participants randomized to each group in the analyses and will
analyse participants in the group to which they were randomized.
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Assessment of heterogeneity
We will inspect forest plots for overlapping CIs and will assess sta-
tistical heterogeneity in each meta-analysis using the I2 and Chi2
statistics. We will regard heterogeneity as: moderate if I² statistic
values are between 30% and 60%; substantial if they are between
50% and 90%; and considerable if they are between 75% and
100% (Higgins 2011c). We will regard a Chi2 test statistic with
a P value of 0.10 or less as indicative of statistically significant
heterogeneity.We will explore clinical andmethodological hetero-
geneity through consideration of the trial populations, methods,
and interventions, and by visualization of trial results.
Assessment of reporting biases
If there are 10 or more trials included in each meta-analysis, we
will investigate reporting biases (such as publication bias) using
funnel plots. We will assess funnel plot asymmetry visually, and
use formal tests for funnel plot asymmetry (Harbord 2006). If we
detect asymmetry in any of these tests or by a visual assessment,
we will explore the reasons for asymmetry.
Data synthesis
We will analyse data using Review Manager 5 (RevMan 2014).
We will use fixed-effect meta-analysis to combine data if hetero-
geneity is absent. If considerable heterogeneity is present, we will
combine data using random-effects meta-analysis and report an
average treatment effect.Wewill decide whether to use fixed-effect
or random-effects models based on the consideration of clinical
andmethodological heterogeneity between trials, as described pre-
viously. We will stratify the analysis by study design. Any studies
conducted in epidemic settings will be considered in a separate
analysis.
Certainty of the evidence
We will assess the certainty of the evidence using the GRADE
approach (Guyatt 2011). We will rate each primary outcome for
RCTs, as described in Balshem 2011.
For non-randomized studies, wewill usedGRADE to rate primary
outcomeswhere there is a low risk of bias from the ROBINS-I tool.
For these studies, we will start with a rating of high certainty, and
downgrade or upgrade our assessment from that point. Where the
following outcome domains are judged to have moderate, high,
or unclear risk of bias, we will begin with a rating of low certainty
of evidence.
• Bias due to confounding.
• Bias due to missing data.
• Bias in selection of the reported result.
We will use the following definitions to assess the certainty of the
evidence.
• High: we are very confident that the true effect lies close to
that of the estimate of the effect.
• Moderate: we are moderately confident in the effect
estimate. The true effect is likely to be close to the estimate of
the effect.
• Low: our confidence in the effect estimate is limited. The
true effect may be substantially different from the estimate of the
effect.
• Very low: we have very little confidence in the effect
estimate. The true effect is likely to be substantially different
from the estimate of effect.
Randomized controlled trials start as high-quality evidence but can
be downgraded if there are valid reasons within the following five
categories: risk of bias, imprecision, inconsistency, indirectness,
and publication bias.
Non-randomized studies can be upgraded (provided they are not
downgraded for any reason) if there is a large effect; a dose-response
effect; and if all plausible residual confounding would reduce a
demonstrated effect or would suggest a spurious effect if no effect
was observed (Balshem 2011).
We will summarize our findings in a ‘Summary of findings’ table.
Subgroup analysis and investigation of heterogeneity
We will explore reasons for substantial heterogeneity using sub-
group analysis. We plan to perform the following subgroup anal-
yses.
• Coverage of IRS:
◦ high (80% to 100%);
◦ moderate (50% to 79%); or
◦ low (less than 50%).
We expect that the coverage of IRS would be an effect modifier
when looking at the efficacy from a community level. Previous
studies have suggested that there is no benefit associated with low
coverage IRS (less than 20%), whereas in areas of high coverage
(greater than 80%), community-wide benefits can be observed
(Larsen 2017).
• Transmission pattern:
◦ stable (characterized by a steady prevalence pattern,
with little variation from one year to another); or
◦ seasonal (transmission that occurs only during some
months of the year and is markedly reduced during other
months) or unstable (epidemic).
In areas of unstable or seasonal malaria transmission, the timing
and frequency of IRS will likely affect its efficacy (Worrall 2007).
Therefore, IRS may be more efficacious in areas of stable trans-
mission, where IRS is less dependent on the timing and frequency
of spraying.
• Resistance to insecticide used for IRS in the study (data for
this can be from within five years of the study period):
◦ present;
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◦ absent; or
◦ no data.
Resistance to various classes of insecticide has been reported since
dichlorodiphenyltrichloroethane (DDT)was first introduced, and
there is increasing evidence that insecticide resistance is asso-
ciated with negative epidemiological outcomes (Ranson 2011;
Protopopoff 2018). Therefore, IRS is likely to be less effective in
areas where there are high levels of resistance.
• Population mobility:
◦ migrant or displaced populations, including refugees,
migrant workers and nomadic people; or
◦ non-migrant populations.
We expect that IRS will be more effective in non-migrant popula-
tions where individuals are more likely to be consistently spending
time in insecticide-sprayed houses.
Sensitivity analysis
We will perform sensitivity analysis on the primary outcomes, to
observe the effect of excluding trials at high risk of bias with regards
to incomplete outcome data. If the ICC value is estimated, we will
undertake sensitivity analyses to investigate the impact of varying
the ICC value on meta-analysis results.
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A D D I T I O N A L T A B L E S
Table 1. WHO-recommended insecticides for indoor residual spraying against malaria vectors
Insecticides and formulations Dosage (g AI/m²)
DDT WP 1 to 2
Malathion WP 2
Fenitrothion WP 2
Pirimiphos-methyl WP, EC 1 to 2
Pirimiphos-methyl CS 1
Bendiocarb WP, WP-SB 0.1 to 0.4
Propoxur WP 1 to 2
Alpha-cypermethrin WP, SC, WG-SB 0.02 to 0.03
Bifenthrin WP 0.025 to 0.05
Cyfluthrin WP 0.02 to 0.05
Deltamethrin WP, WG, WG-SB, SC-PE 0.02 to 0.025
Etofenprox WP 0.1 to 0.3
Lambda-cyhalothrin WP, CS 0.02 to 0.03
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Table 1. WHO-recommended insecticides for indoor residual spraying against malaria vectors (Continued)
SumiShield WG 0,03
Chlorfenapyr 240 SC: the current assessments of Chlorfenapyr SC (class group: pyrrole) are available in the report of the 16thWHOPES
Working Group meeting, 22-30 July 2013, and the report of the 17th WHOPESWorking Group meeting, 15-19 September 2014
(WHO 2013; WHO 2014). Table modified from WHO 2018c.
Abbreviations: AI: active ingredient CS: capsule suspension; DDT: dichloro-diphenyl-trichlorethane; EC: emulsifiable concentrate;
IRS: indoor residual spraying; SC: suspension concentrate; SC-PE: polymer-enhanced suspension concentrate; WHO: World Health
Organization;WG:water-dispersible granule;WG-SB:water-dispersible granules packaged inwater-soluble bags;WP: wettable powder;
WP-SB: wettable powder in sealed water-soluble bags.
Table 2. Haemoglobin levels used to diagnose anaemia (WHO 2011)
Population Non-anaemiaa Anaemiaa
Mild Moderate Severe
Children 6 to 59months
of age
110 or higher 100 to 109 70 to 99 70
Children 5 to 11 years of
age
115 or higher 110 to 114 80 to 109 80
Children 12 to 14 years
of age
120 or higher 110 to 119 80 to 109 80
Non-pregnant
women (15 years of age
and above)
120 or higher 110 to 119 80 to 109 80
Pregnant women 110 or higher 100 to 109 70 to 99 70
Men (15 years of age and
above)
130 or higher 110 to 129 80 to 109 80
aHaemoglobin in g/L.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Search set Search terms
1 Malaria* Title/Abstract , [Mesh]
2 Anopheles Title/Abstract , [Mesh]
3 1 or 2
4 “indoor residual spray*” or IRS Title/Abstract
5 “house spraying” or “house spray” Title/Abstract
6 “Pyrethrins/administration and dosage”[Mesh]
7 “Mosquito Control/instrumentation”[Mesh] OR “Mosquito Control/methods”[Mesh] )
8 ( “Insecticides/instrumentation”[Mesh] OR “Insecticides/therapeutic use”[Mesh] )
9 4 or 5or 6 or 7
10 3 and 9
11 “Randomized Controlled Trial” [Publication Type] OR “Controlled Clinical Trial” [Publication Type]
12 randomized or placebo or randomly or trial or groups Title/Abstract
13 drug therapy [sh]
14 “Interrupted Time Series Analysis”[Mesh]
15 “Controlled Before-After Studies”[Mesh
16 “time series” Title/Abstract
17 “cross-over studies”[MeSH] or crossover or cross-over Title/Abstract
18 “longitudinal studies”[MeSH]
19 Longitudinal or cohort* Title/Abstract
20 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
21 10 and 20
This is the preliminary search strategy for MEDLINE (PubMed). It will be adapted for other electronic databases. We will report all
search strategies in full in the final review version.
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Appendix 2. Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool: protocol
stage
ROBINS-I tool (Stage I): protocol stage
Specify the review question
Participants Anyone living in an area with malaria.
Experimental intervention IRS using the World Health Organization (WHO)-recommended dosage (WHO 2015).
Comparator No other insecticidal malaria vector control. Any other interventions for malaria control will have to
be balanced in all study arms
Outcomes Malaria case incidence, incidence of new malaria infections, malaria parasite prevalence
List the confounding domains relevant to all or most studies
• Socioeconomic status: those of lower socioeconomic status may be less likely to live in homes with walls appropriate for IRS and
therefore less likely to be selected for the intervention group. Socioeconomic status is considered a prognostic factor for malaria (Somi
2007).
• Geographical location: those living in certain geographic regions may live in houses that are more appropriate or more
convenient for IRS spraying and therefore may be more likely to be selected for the intervention group. For example, houses that are
better connected to roads might be more convenient to spray. Malaria transmission is also heterogenous across different geographical
regions and can therefore be a predictor of malaria risk (Bousema 2012).
• Population mobility: more mobile populations may be less likely to be chosen for studies due to inconveniences associated with
measuring clinical outcomes. Population movement is also a risk factor for malaria; therefore those individuals chosen for the
intervention arm may be at lower risk of malaria (Martens 2000).
List cointerventions that could be different between intervention groups and that could impact on outcomes
• Use of other (non-insecticidal) vector control tools: individuals receiving the intervention may feel less inclined to use other
vector control interventions such as bed nets.
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